Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Issue 11 (November 2018)

• Record Type: Journal Article
• Authors: Quadros, C.A.; Laporte, G.A.; Huguenin, J.F.L.; Barreto, E.J.S.S.; Barros, A.V.; Oliveira, A.F.; Carvalho, A.L.L.; Petruzziello, A.; Paula, A.C.; Urbano-Ruiz, A.; Santos, C.C.; Galhardo, C.A.V.G.; Johnson, L.F.P.; Vendrame, C.D.; Santana, D.P.; Akaishi, E.; Ferreira, F.O.; Queiroz, F.L.; Miranda, F.A.C.L.; Lissa, F.C.T.; Sarmento, B.J.Q.; Nascimento, G.J.S.; Novaski, G.L.; Meinhardt, J.G.J.; Mali-Junior, J.; Barreto-Junior, J.V.; Salomão-Junior, L.R.; Pinto, C.V.; Cavalla, C.; Sanchez-Loria, F.A.; Coelho-Junior, M.J.P.; Perrotta, F.M.; Flores-Ayala, E.G.; Martinez-Said, H.; De-La-Fuente, H.; Lopez-Basave, H.N.; Sandoval-Jauregui, J.; Butte, J.M.; Florez, J.P.; Ruso, M.L.; Belotto, M.; Matus, R.R.G.; Souza-Filho, O.; Camara, P.C.; Seitenfus, R.; Anselmi-Junior, R.A.; Cutait, R.; Leal, R.M.L.V.; Boff, M.F.; Sabbag, R.; Silva, R.G.; Morán, A.R.; Salcedo-Hernandez, R.A.; Aguiar-Junior, S.; Ramirez, S.R.; Reis, T.J.C.C.; Batista, T.P.; Francischetto, T.; Gava, V.G.; Arias, F.; Castro, J.M.M.; Matus, R.R.G.; Pacheco, M.; García, M.M.; Venancio, C.; Leonardi, P.C.; Zanatto, R.M.; Wainstein, A.J.A.; Cordeiro, E.Z.; Perina, A.L.F.; Figueiredo, P.H.M.; Pereira, L.F.; Molina, M.E.; Vazquez, V.L.; Teixeira-Junior, F.J.R.;
• Is Part Of: European journal of surgical oncology. Volume 44:Issue 11(2018)
• Page Start: 1800
• Page End: 1804
• Publication Date: 2018-11
• Subjects: Cytoreductive surgery -- HIPEC -- Peritoneal carcinomatosis -- Intraperitoneal chemotherapy -- Peritoneal metastasis -- Peritoneal disease; CRS cytoreductive surgery -- HIPEC hyperthermic intraperitoneal chemotherapy -- PD peritonal disease -- LA Latin American -- LARPD Latin American Registry of Peritoneal Diseases -- PM peritoneal metastasis -- PCI Peritoneal Cancer Index -- ECOG Eastern Cooperative Oncology Group, performance status criteria -- CC0/CC1/CC2/CC3 completeness of cytoreduction score CC. CC0: no visible peritoneal carcinomatosis after CRS. CC-1: nodules persisting <2.5 mm after CRS. CC-2: nodules persisting between 2.5 mm and 2.5 cm. CC-3: nodules persisting >2.5 cm -- CT computed tomography -- MRI magnetic resonance imaging -- PET-CT positron emission computed tomography -- CEA carcinoembryonic antigen -- CA 125 cancer antigen 125 -- CA 19.9 carbohydrate antigen 19-9 -- IP Intraperitoneal; Oncology -- Periodicals; Cancer -- Surgery -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Cancérologie -- Périodiques; Oncologie; Chirurgie (geneeskunde); Electronic journals; Electronic journals -- Sciences; Electronic journals -- Medicine; Electronic journals; 616.994059005
• DOI: 10.1016/j.ejso.2018.06.029
• Languages: English
• ISSNs: 0748-7983

Abstract

Abstract: Introduction: A combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as a treatment option in patients with peritoneal metastasis of colorectal, ovarian, gastric cancers and sarcomas and as a current standard treatment for pseudomyxoma peritonei and peritoneal mesothelioma. There is a need to standardize its indication, drugs selection along with their concentrations and ways to deliver peritoneal chemotherapy solutions for best outcomes. Aim of the study: To investigate the current practice of Latin American (LA) Centers in which peritoneal diseases (PD) are treated. Patient and Methods: All centers from Latin American Registry of Peritoneal Diseases (LARPD) were invited to participate in a two rounds online survey, to describe their current practice in all indications of CRS with HIPEC for PD. Results: 76 out of 84 LARPD&#39;s centers answered the survey, with a response rate of 90, 5%. The results represent the current practice of 248 surgeons that are members of LARPD&#39;s centers, in 8 LA countries, that at the time of the study had treated 2682 patients with CRS with HIPEC. All current practice aspects including indications, contra-indications, patient selection, methods of peritoneal chemotherapy delivery and treatment protocols are described in this manuscript. Conclusions: This survey is the first LA effort to publish current practice indications and treatment protocols of PD. Achieving consensus of best therapeutic options is essential to provide the best possible outcomes for patients with PD who could benefit from CRS with HIPEC therefore aiming at standardization of the procedure.